Cargando…

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

BACKGROUND: Accurate assessment of predictive biomarker expression is critical in patient selection in clinical trials or clinical practice. However, changes in biomarker expression may occur after treatment. The aim of the present study was to evaluate the effects of chemotherapy on MET expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Haiyan, Tian, Tiantian, Sheng, Yuling, Peng, Zhi, Li, Zhongwu, Wang, Jingyuan, Li, Yanyan, Zhang, Cheng, Gao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453156/ https://www.ncbi.nlm.nih.gov/pubmed/34557411 http://dx.doi.org/10.3389/fonc.2021.719217

Ejemplares similares

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma
por: Xu, Yingying, et al.
Publicado: (2015)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
por: Peng, Zhi, et al.
Publicado: (2014)

MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
por: Ye, Wen, et al.
Publicado: (2022)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma
por: Wu, Ju-gang, et al.
Publicado: (2014)

Opportunities and challenges of targeting c-Met in the treatment of digestive tumors
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
por: Gu, Yangjun, et al.
Publicado: (2023)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
por: Jin, Yangbing, et al.
Publicado: (2021)

Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance
por: Yuan, Jiajia, et al.
Publicado: (2016)

MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression
por: Perrone, Clara, et al.
Publicado: (2022)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
por: Su, Pengxiao, et al.
Publicado: (2023)

MACC1 and MET as markers associated with progression and metastasis in cutaneous melanoma
por: Zhou, Yan, et al.
Publicado: (2023)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance
por: Guo, Tiankang, et al.
Publicado: (2013)

Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer
por: Kang, Byung Woog, et al.
Publicado: (2015)

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
por: Ko, Jihoon, et al.
Publicado: (2022)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal‐epithelial transition factor (MET): A case report
por: He, XinCheng, et al.
Publicado: (2022)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
por: Kitowska, Kamila, et al.
Publicado: (2021)

Can the sustainable development goals for cancer be met in Brazil? A population-based study
por: De Camargo Cancela, Marianna, et al.
Publicado: (2023)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis
por: Peng, Jifeng, et al.
Publicado: (2016)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
por: Sun, Boyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tq79k23udi062njkcil8pbnub9